Just when we thought weight-loss drug makers had hit their peak, a new study's findings show that they’re just getting started.
What happened: Novo Nordisk’s blockbuster obesity drug WeGovy not only helps people lose weight but cuts the risk of heart attacks or strokes by 20%, according to the findings of a company-funded study. Sales were already up 25% in the first three months of 2023.